Anabolic Steroids/Hormones
Boldenone Undecylenate (Equipoise)
Also called EQ · Equipoise · Boldenone
Equipoise, or EQ, is discussed for gradual size gains, a more vascular look and better training endurance. Appetite is another attraction, but users disagree about whether it increases. The practical catch is a long-lasting injection and mixed experiences with anxiety, libido and estrogen-related symptoms.
Dosage & duration
A named nonmedical profile example, not human prescribing guidance.
Reported bodybuilding add-on use
Reported use · unapproved regimen- Dose
- 400 mg total per week, illustrated as two 200 mg amounts
- How often
- The same profile illustrates 200 mg twice weekly
- How long
- No fixed course length stated
An author-described nonmedical example, not a safe lower limit, common-use survey or validated cycle.
More quick facts
- Why people seek it
- Muscle, stamina and a vascular look
- Appetite question
- Not everyone gets hungrier
- The trade-off
- Slow changes and mixed tolerance
Equipoise at a glance
Muscle, stamina and the appetite question
-
Beyond scale weight
People seek gradual size gains, visible veins and better training stamina.
-
Hunger is inconsistent
Some report strong hunger; others notice no appetite boost.
-
Slow changes matter
The longer-release routine appeals for convenience, but users describe frustration when changing course.
Why EQ appeals beyond scale weight
The attraction is often a combination of size, visible veins and feeling able to train longer. Some users describe it as gradual rather than dramatic. Those are experience reports from multi-drug use, not a promise that EQ produces a particular look or endurance gain.
Does it really increase appetite?
Reports go in both directions. Some users describe relentless hunger, which can be inconvenient rather than useful; a recent account described no appetite boost at all. It should not be treated as a dependable appetite treatment or a guarantee of an easier bulk.
Why the estrogen discussion gets confusing
Some people report low-estrogen symptoms; others say EQ did not control estrogen for them. Anxiety, fatigue or libido changes cannot identify a hormone level on their own. Personal ratios and bloodwork anecdotes do not establish a reliable substitute for prescribed treatment.
The long-release trade-off
Fewer injection days can sound convenient, but users also describe frustration when they want to change course. The relative plot illustrates assumed overlap over time. It cannot predict appetite, mental wellbeing, blood counts or a safe duration of use.
Model details: Boldenone Undecylenate (Equipoise) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 336 hours
- Absorption half-life assumed
- 84 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (84 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- 336 h is retained only as an assumed human scenario; the equine paper reports 123 h terminal, not 14 days.
- Oil/ester preparation, species scaling and dose-to-human concentration are unresolved.
- Soma 2007 boldenone/stanozolol in horses
IM equine exposures: boldenone 1.1 mg/kg and stanozolol 0.55 mg/kg; not human calibration.
- Schänzer 1992 boldenone metabolism in men
Oral parent doses 11–80 mg, urinary metabolite analysis; neither cypionate nor undecylenate plasma PK.
- 21 CFR 522.204 Boldenone
Veterinary horse injectable context, not human PK.
boldenone-undecylenate-relative-timing-2026-10 · version 1
Safety and interaction notes Read the limitations and discuss clinical questions with a professional
- Aromatizes
- Yes
- DHT derivative
- No
Common questions
Does EQ always increase appetite?
It is a common reported reason for use, but individual accounts vary and do not guarantee an effect.
Is Equipoise the same as boldenone cypionate?
They involve the same parent steroid with different esters and preparations. Do not assume matching release, dosing or product quality.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-10, 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Why people seek it
- Reported goals include a steadier bulk and less fatigue between sets.
- Appetite question
- Some welcome extra hunger, some find it excessive, and others notice little change.
- The trade-off
- Feeling energetic in the gym does not guarantee feeling well outside it.
- 1. Soma 2007 boldenone/stanozolol in horses
IM equine exposures: boldenone 1.1 mg/kg and stanozolol 0.55 mg/kg; not human calibration.
- 2. Schänzer 1992 boldenone metabolism in men
Oral parent doses 11–80 mg, urinary metabolite analysis; neither cypionate nor undecylenate plasma PK.
- 3. 21 CFR 522.204 Boldenone
Veterinary horse injectable context, not human PK.
- 4. 21 CFR 522.204 — boldenone veterinary conditions of use
Current federal veterinary entry: injectable boldenone undecylenate for horses under veterinary direction. Does not establish a human-use regimen.
- 5. Soma et al. 2007 — injected boldenone and stanozolol in horses
Abstract checked. Equine study; reported boldenone terminal half-life about 123 hours is not the site’s assumed 14-day human profile.
- 6. USADA — boldenone information
No FDA-approved human use; sport and health information. Veterinary use does not establish human dosing.
- 7. HAARLEM — blood pressure, lipids and hematocrit
Original prospective AAS-user cohort supports attention to cardiovascular markers and blood counts; does not isolate EQ-specific risk.
Keep reading
Related compounds and examples
Related compounds
Boldenone Cypionate
Boldenone cypionate attracts people interested in EQ-style muscle and performance goals without Equipoise’s long-release commitment. People also report injection discomfort and unpredictable libido or estrogen-related experiences. The hoped-for timing advantage has not been established in a human comparison study.
Dihydroboldenone (DHB)
DHB, also called 1-testosterone, attracts bodybuilders looking for muscle fullness, strength and a leaner appearance. It is often compared with Primo or EQ, including by readers looking for an alternative to Primo. User experiences split over whether those benefits outweigh injection pain, fatigue and feeling unwell.
Testosterone Enanthate
Testosterone enanthate is used to replace testosterone when low levels cause symptoms. Bodybuilders use higher amounts to pursue muscle and strength. The practical questions are how much is being used, how often to inject, and how the schedule affects peaks, troughs and treatment burden.